Quantum Biopharma Ltd. 6-K Filing
Ticker: QNTM · Form: 6-K · Filed: Nov 3, 2025 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Nov 3, 2025 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Quantum Biopharma Ltd. (ticker: QNTM) to the SEC on Nov 3, 2025.
How long is this filing?
Quantum Biopharma Ltd.'s 6-K filing is 1 pages with approximately 365 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 365 words · 1 min read · ~1 pages · Grade level 9.3 · Accepted 2025-10-31 20:06:51
Filing Documents
- f6k_103125.htm (6-K) — 9KB
- exh_51.htm (EX-5.1) — 25KB
- exh_991.htm (EX-99.1) — 13KB
- gar.jpg (GRAPHIC) — 5KB
- 0001171843-25-006869.txt ( ) — 54KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: October 31, 2025 /s/ Donal Carroll Donal Carroll Chief Financial Officer EXHIBIT INDEX Exhibit Description of Exhibit 10.1 At The Market Offering Agreement dated February 16, 2024 between Quantum BioPharma Ltd. (formerly FSD Pharma Inc.) and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 10.1 to the Company's Form 6-K furnished with the SEC on February 20, 2024) 23.1 Consent of Garfinkle Biderman LLP (included in Exhibit 5.1) 99.1 Press Release - October 31, 2025 - Quantum BioPharma Ltd. Announces US ATM Offering